It is used in first-line treatment of patients with distinct types of metastatic (EGFR mutation positive) non-small cell lung carcinoma (NSCLC), developed by Boehringer Ingelheim. It acts as an irreversible covalent inhibitor of the receptor tyrosine kinases epidermal growth factor receptor (EGFR) and erbB-2 (HER2).It has received regulatory approval for use as a treatment for non-small cell lung cancer, although there is emerging evidence to support its use in other cancers such as breast cancer.
Brand name: Xovoltib
Active Ingeridents: Afatinib
Company Name: Boehringer Ingelheim
Package: 7 tabs in strips
Strength : 20mg, 30mg ,40mg & 50mg
Mechanism of action:
Xovoltib (Afatinib) is a protein kinase inhibitor that also irreversibly inhibits human epidermal growth factor receptor 2 and epidermal growth factor receptor (EGFR) kinases. Xovoltib (Afatinib) is not only active against EGFR mutations targeted by first generation TKIs like erlotinib or gefitinib, but also against mutations such as T790M which are not sensitive to these standard therapies. Because of its additional activity against receptor 2, it is being investigated for breast cancer as well as other EGFR and receptor 2 driven cancers.
Dosage and Administration:
Xovoltib (Afatinib) is a pill, taken by mouth.
Take Xovoltib (Afatinib) on an empty stomach at least 1 hour before or 2 hours after a meal.
Take Xovoltib (Afatinib) exactly as prescribed.
Swallow Xovoltib (Afatinib) tablets whole with at least 8 ounces of water. Do not crush or dissolve tablets.
Do not change your dose or stop Xovoltib (Afatinib) unless your health care provider tells you to.
If you miss a dose and your next dose is due in: Less than 12 hours, take your next dose at the normal time. Do not make up the next dose.
12 hours or more, take the missed dose as soon as you remember. Take your next dose at the normal time.
Do not take more than 1 dose of Xovoltib (Afatinib) at one time. Call your health care provider and go to the emergency room right away if you take too much.
Store at room temperature (68° F to 77° F); keep medication in original bottle; protect from high humidity, moisture and light.
The amount of Xovoltib (Afatinib) that you will receive depends on many factors, including your general health or other health problems, and the type of cancer or condition you have. Your doctor will determine your exact Xovoltib (Afatinib) dosage and schedule
The following side effects are common (occurring in greater than 30%) for patients taking Xovoltib (Afatinib):
* Acneiform eruption (group of skin conditions resembling acne)
* Mouth sores,Paronychia (infection of nails),Dry mouth
These are less common side effects (occurring in 10-29%) for patients receiving Xovoltib (Afatinib):
* Decreased appetite,Itching,Weight loss,Nose bleeds,Cystitis (bladder infection),Cheilitis (inflammation of the lips),Fever,Hypokalemia (low potassium),Conjunctivitis (pink eye),Rhinorrhea (runny nose)
* Elevated liver enzymes
Gilotrif (Afatinib) room temperature away from moisture and heat
Before startingXovoltib (Afatinib) treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc.).
While taking Xovoltib (Afatinib), do not receive any kind of immunization or vaccination without your doctor’s approval.
Limit your time in the sun. Xovoltib (Afatinib) can make your skin sensitive to sunlight. A severe sunburn, rash or worsening acne can occur with too much exposure. Remember to use sunscreen and wear a hat and clothes that cover as much of your skin as possible while taking Xovoltib (Afatinib).
Inform your health care professional if you are pregnant or may be pregnant prior to starting this treatment. Pregnancy category D (may be hazardous to the fetus. Women who are pregnant or become pregnant must be advised of the potential hazard to the fetus.)
Xovoltib is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.